Tekla Capital Management LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.

Quarter-by-quarter ownership
Tekla Capital Management LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$575,861
-17.6%
52,0670.0%0.02%
-14.8%
Q1 2023$699,260
+8.6%
52,0670.0%0.03%
+12.5%
Q4 2022$644,069
-11.3%
52,0670.0%0.02%
-20.0%
Q3 2022$726,000
+1.0%
52,0670.0%0.03%
+7.1%
Q2 2022$719,000
-15.1%
52,0670.0%0.03%
-6.7%
Q1 2022$847,000
-0.1%
52,0670.0%0.03%
+11.1%
Q4 2021$848,000
+9.7%
52,0670.0%0.03%
+8.0%
Q3 2021$773,000
-49.8%
52,067
-32.4%
0.02%
-50.0%
Q2 2021$1,539,000
-13.5%
77,0670.0%0.05%
-18.0%
Q1 2021$1,779,000
-6.6%
77,0670.0%0.06%
-9.0%
Q4 2020$1,904,000
-40.4%
77,0670.0%0.07%
-44.2%
Q3 2020$3,195,000
-13.5%
77,0670.0%0.12%
-14.9%
Q2 2020$3,692,000
+70.4%
77,067
+123.9%
0.14%
+43.9%
Q1 2020$2,167,000
-49.2%
34,4140.0%0.10%
-39.1%
Q4 2019$4,265,000
+86.7%
34,4140.0%0.16%
+61.0%
Q3 2019$2,284,000
-46.7%
34,414
-36.1%
0.10%
-42.9%
Q2 2019$4,285,000
-35.4%
53,857
-9.1%
0.18%
-34.9%
Q1 2019$6,631,000
+393.0%
59,275
+344.1%
0.27%
+363.8%
Q4 2018$1,345,000
-81.2%
13,348
-89.2%
0.06%
-77.3%
Q3 2017$7,151,000123,2000.26%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders